

WHAT IS CLAIMED IS:

1. A method of breaking-down an immunological tolerance to interferon gamma-inducible protein 10 in a subject, the method comprising administering to, or expressing within, the subject an amount of interferon gamma-inducible protein 10, or an immunological portion thereof, sufficient to elicit sufficient anti-interferon gamma-inducible protein 10 antibodies so as to break-down the immunological tolerance to interferon gamma-inducible protein 10.

2. The method of claim 1, wherein expressing within the subject said amount of interferon gamma-inducible protein 10 is by generating in, or introducing into, the subject cells expressing recombinant interferon gamma-inducible protein 10, or an immunological portion thereof,.

3. The method of claim 1, wherein generating in the subject cells expressing recombinant interferon gamma-inducible protein 10, or an immunological portion thereof, is by vaccinating the subject with an

expression construct encoding interferon gamma-inducible protein 10, or said immunological portion thereof.

4. A method of generating self specific immunity to interferon gamma-inducible protein 10 in a subject, the method comprising administering to, or expressing within, the subject an amount of interferon gamma-inducible protein 10, or an immunological portion thereof, sufficient to elicit sufficient anti-interferon gamma-inducible protein 10 antibodies so as to generate self specific immunity to interferon gamma-inducible protein 10.

5. The method of claim 4, wherein expressing within the subject said amount of interferon gamma-inducible protein 10 is by generating in, or introducing into, the subject cells expressing recombinant interferon gamma-inducible protein 10, or an immunological portion thereof,.

6. The method of claim 4, wherein generating in the subject cells expressing recombinant interferon gamma-inducible protein 10, or an

immunological portion thereof, is by vaccinating the subject with an expression construct encoding interferon gamma-inducible protein 10, or said immunological portion thereof.

7. A method of preventing or treating an autoimmune disease in which activity of interferon gamma-inducible protein 10 is pivotal in a subject, the method comprising administering to, or expressing within, the subject an amount of interferon gamma-inducible protein 10, or an immunological portion thereof, sufficient to elicit sufficient anti-interferon gamma-inducible protein 10 antibodies so as to treat or prevent the autoimmune disease.

8. The method of claim 7, wherein expressing within the subject said amount of interferon gamma-inducible protein 10 is by generating in, or introducing into, the subject cells expressing recombinant interferon gamma-inducible protein 10, or an immunological portion thereof,.

9. The method of claim 7, wherein generating in the subject cells expressing recombinant interferon gamma-inducible protein 10, or an immunological portion thereof, is by vaccinating the subject with an expression construct encoding interferon gamma-inducible protein 10, or said immunological portion thereof.

10. A method of restricting a polarization of myelin basic protein specific T cells into Th2 cells in a subject, the method comprising administering to, or expressing within, the subject an amount of interferon gamma-inducible protein 10, or an immunological portion thereof, sufficient to elicit sufficient anti-interferon gamma-inducible protein 10 antibodies so as to restrict a polarization of myelin basic protein specific T cells into Th2 cells.

11. The method of claim 10, wherein expressing within the subject said amount of interferon gamma-inducible protein 10 is by generating in, or introducing into, the subject cells expressing recombinant interferon gamma-inducible protein 10, or an immunological portion thereof.

12. The method of claim 10, wherein generating in the subject cells expressing recombinant interferon gamma-inducible protein 10, or an immunological portion thereof, is by vaccinating the subject with an expression construct encoding interferon gamma-inducible protein 10, or said immunological portion thereof.

13. A method of inducing protective immunity against multiple sclerosis in a subject, the method comprising administering to, or expressing within, the subject an amount of interferon gamma-inducible protein 10, or an immunological portion thereof, sufficient to elicit sufficient anti-interferon gamma-inducible protein 10 antibodies, so as to induce protective immunity against multiple sclerosis in the subject.

14. The method of claim 13, wherein expressing within the subject said amount of interferon gamma-inducible protein 10 is by generating in, or introducing into, the subject cells expressing recombinant interferon gamma-inducible protein 10, or an immunological portion thereof.

15. The method of claim 13, wherein generating in the subject cells expressing recombinant interferon gamma-inducible protein 10, or an immunological portion thereof, is by vaccinating the subject with an expression construct encoding interferon gamma-inducible protein 10, or said immunological portion thereof.

16. A method of preventing or treating multiple sclerosis in a subject, the method comprising administering to, or expressing within, the subject an amount of interferon gamma-inducible protein 10, or an immunological portion thereof, sufficient to elicit sufficient anti-interferon gamma-inducible protein 10 antibodies so as to treat or prevent multiple sclerosis.

17. The method of claim 16, wherein expressing within the subject said amount of interferon gamma-inducible protein 10 is by generating in, or introducing into, the subject cells expressing recombinant interferon gamma-inducible protein 10, or an immunological portion thereof.

18. The method of claim 16, wherein generating in the subject cells expressing recombinant interferon gamma-inducible protein 10, or an immunological portion thereof, is by vaccinating the subject with an expression construct encoding interferon gamma-inducible protein 10, or said immunological portion thereof.

19. A pharmaceutical composition for breaking-down an immunological tolerance to interferon gamma-inducible protein 10 in a subject, the pharmaceutical composition comprising, a pharmaceutically acceptable carrier approved for medical or veterinary administration and, as an active ingredient, an amount of interferon gamma-inducible protein 10, or an immunological portion thereof, or of an expression construct encoding said interferon gamma-inducible protein 10, or said immunological portion thereof, sufficient to elicit sufficient anti-interferon gamma-inducible protein 10 antibodies so as to break-down the immunological tolerance to interferon gamma-inducible protein 10.

20. The pharmaceutical composition of claim 19, packaged and identified for treatment of a disease or condition in which interferon gamma-inducible protein 10 plays a pivotal role.

21. A pharmaceutical composition for generating self specific immunity to interferon gamma-inducible protein 10 in a subject, the pharmaceutical composition comprising, a pharmaceutically acceptable carrier approved for medical or veterinary administration and, as an active ingredient, an amount of interferon gamma-inducible protein 10, or an immunological portion thereof, or of an expression construct encoding said interferon gamma-inducible protein 10, or said immunological portion thereof, sufficient to elicit sufficient anti-interferon gamma-inducible protein 10 antibodies so as to generate self specific immunity to interferon gamma-inducible protein 10.

22. The pharmaceutical composition of claim 21, packaged and identified for treatment of a disease or condition in which interferon gamma-inducible protein 10 plays a pivotal role.

23. A pharmaceutical composition for preventing or treating an autoimmune disease in which activity of interferon gamma-inducible protein 10 is pivotal in a subject, the pharmaceutical composition comprising, a pharmaceutically acceptable carrier approved for medical or veterinary administration and, as an active ingredient, an amount of interferon gamma-inducible protein 10, or an immunological portion thereof, or of an expression construct encoding said interferon gamma-inducible protein 10, or said immunological portion thereof, sufficient to elicit sufficient anti-interferon gamma-inducible protein 10 antibodies so as to treat or prevent the autoimmune disease.

24. The pharmaceutical composition of claim 23, packaged and identified for treatment of a disease or condition in which interferon gamma-inducible protein 10 plays a pivotal role.

25. A pharmaceutical composition for restricting a polarization of myelin basic protein specific T cells into Th2 cells in a subject, the pharmaceutical composition comprising, a pharmaceutically acceptable carrier approved for medical or veterinary administration and, as an active

ingredient, an amount of interferon gamma-inducible protein 10, or an immunological portion thereof, or of an expression construct encoding said interferon gamma-inducible protein 10, or said immunological portion thereof, sufficient to elicit sufficient anti-interferon gamma-inducible protein 10 antibodies so as to restrict a polarization of myelin basic protein specific T cells into Th2 cells.

26. The pharmaceutical composition of claim 25, packaged and identified for treatment of a disease or condition in which interferon gamma-inducible protein 10 plays a pivotal role.

27. A pharmaceutical composition for inducing protective immunity against multiple sclerosis in a subject, the pharmaceutical composition comprising, a pharmaceutically acceptable carrier approved for medical or veterinary administration and, as an active ingredient, an amount of interferon gamma-inducible protein 10, or an immunological portion thereof, or of an expression construct encoding said interferon gamma-inducible protein 10, or said immunological portion thereof, sufficient to elicit sufficient anti-interferon gamma-inducible protein 10

antibodies, so as to induce protective immunity against multiple sclerosis in the subject.

28. The pharmaceutical composition of claim 27, packaged and identified for treatment of a disease or condition in which interferon gamma-inducible protein 10 plays a pivotal role.

30. A pharmaceutical composition for preventing or treating multiple sclerosis in a subject, the pharmaceutical composition comprising, a pharmaceutically acceptable carrier approved for medical or veterinary administration and, as an active ingredient, an amount of interferon gamma-inducible protein 10, or an immunological portion thereof, or of an expression construct encoding said interferon gamma-inducible protein 10, or said immunological portion thereof, sufficient to elicit sufficient anti-interferon gamma-inducible protein 10 antibodies so as to treat or prevent multiple sclerosis.

31. The pharmaceutical composition of claim 30, packaged and identified for treatment of a disease or condition in which interferon gamma-inducible protein 10 plays a pivotal role.

32. A method of breaking-down an immunological tolerance to interferon gamma-inducible protein 10 in a subject, the method comprising administering to the subject anti-interferon gamma-inducible protein 10 antibodies in an amount sufficient to break-down the immunological tolerance to interferon gamma-inducible protein 10.

33. A method of generating specific immunity to interferon gamma-inducible protein 10 in a subject, the method comprising administering to the subject anti-interferon gamma-inducible protein 10 antibodies in an amount sufficient to generate self specific immunity to interferon gamma-inducible protein 10.

34. A method of preventing or treating an autoimmune disease in which activity of interferon gamma-inducible protein 10 is pivotal in a subject, the method comprising administering to the subject anti-interferon

gamma-inducible protein 10 antibodies in an amount sufficient to treat or prevent the autoimmune disease.

35. A method of restricting a polarization of myelin basic protein specific T cells into Th2 cells in a subject, the method comprising administering to the subject anti-interferon gamma-inducible protein 10 antibodies in an amount sufficient to restrict a polarization of myelin basic protein specific T cells into Th2 cells.

36. A method of inducing protective immunity against multiple sclerosis in a subject, the method comprising administering to the subject anti-interferon gamma-inducible protein 10 antibodies in an amount sufficient to induce protective immunity against multiple sclerosis in the subject.

37. A method of preventing or treating multiple sclerosis in a subject, the method comprising administering to the subject anti-interferon gamma-inducible protein 10 antibodies in an amount sufficient to treat or prevent multiple sclerosis.

38. A pharmaceutical composition for breaking-down an immunological tolerance to interferon gamma-inducible protein 10 in a subject, the pharmaceutical composition comprising, a pharmaceutically acceptable carrier approved for medical or veterinary administration and, as an active ingredient, anti-interferon gamma-inducible protein 10 antibodies in an amount sufficient to break-down the immunological tolerance to interferon gamma-inducible protein 10.

39. The pharmaceutical composition of claim 38, packaged and identified for treatment of a disease or condition in which interferon gamma-inducible protein 10 plays a pivotal role.

40. A pharmaceutical composition for generating self specific immunity to interferon gamma-inducible protein 10 in a subject, the pharmaceutical composition comprising, a pharmaceutically acceptable carrier approved for medical or veterinary administration and, as an active ingredient, anti-interferon gamma-inducible protein 10 antibodies in an amount sufficient to generate self specific immunity to interferon gamma-inducible protein 10.

41. The pharmaceutical composition of claim 40, packaged and identified for treatment of a disease or condition in which interferon gamma-inducible protein 10 plays a pivotal role.

42. A pharmaceutical composition for preventing or treating an autoimmune disease in which activity of interferon gamma-inducible protein 10 is pivotal in a subject, the pharmaceutical composition comprising, a pharmaceutically acceptable carrier approved for medical or veterinary administration and, as an active ingredient, anti-interferon gamma-inducible protein 10 antibodies in an amount sufficient to treat or prevent the autoimmune disease.

43. The pharmaceutical composition of claim 42, packaged and identified for treatment of a disease or condition in which interferon gamma-inducible protein 10 plays a pivotal role.

44. A pharmaceutical composition for restricting a polarization of myelin basic protein specific T cells into Th2 cells in a subject, the pharmaceutical composition comprising, a pharmaceutically acceptable

carrier approved for medical or veterinary administration and, as an active ingredient, anti-interferon gamma-inducible protein 10 antibodies in an amount sufficient to restrict a polarization of myelin basic protein specific T cells into Th2 cells.

45. The pharmaceutical composition of claim 44, packaged and identified for treatment of a disease or condition in which interferon gamma-inducible protein 10 plays a pivotal role.

46. A pharmaceutical composition for inducing protective immunity against multiple sclerosis in a subject, the pharmaceutical composition comprising, a pharmaceutically acceptable carrier approved for medical or veterinary administration and, as an active ingredient, anti-interferon gamma-inducible protein 10 antibodies in an amount sufficient to induce protective immunity against multiple sclerosis in the subject.

47. The pharmaceutical composition of claim 46, packaged and identified for treatment of a disease or condition in which interferon gamma-inducible protein 10 plays a pivotal role.

48. A pharmaceutical composition for preventing or treating multiple sclerosis in a subject, the pharmaceutical composition comprising, a pharmaceutically acceptable carrier approved for medical or veterinary administration and, as an active ingredient, anti-interferon gamma-inducible protein 10 antibodies in an amount sufficient to treat or prevent multiple sclerosis.

49. The pharmaceutical composition of claim 48, packaged and identified for treatment of a disease or condition in which interferon gamma-inducible protein 10 plays a pivotal role.

50. A method of breaking-down an immunological tolerance to interferon gamma-inducible protein 10 in a subject, the method comprising directly or indirectly introducing anti-interferon gamma-inducible protein

10 antibodies to the subject in an amount sufficient to break-down the immunological tolerance to interferon gamma-inducible protein 10.

51. A method of generating specific immunity to interferon gamma-inducible protein 10 in a subject, the method comprising directly or indirectly introducing anti-interferon gamma-inducible protein 10 antibodies to the subject in an amount sufficient to generate self specific immunity to interferon gamma-inducible protein 10.

52. A method of preventing or treating an autoimmune disease in which activity of interferon gamma-inducible protein 10 is pivotal in a subject, the method comprising directly or indirectly introducing anti-interferon gamma-inducible protein 10 antibodies to the subject in an amount sufficient to treat or prevent the autoimmune disease.

53. A method of restricting a polarization of myelin basic protein specific T cells into Th2 cells in a subject, the method comprising directly or indirectly introducing anti-interferon gamma-inducible protein

10 antibodies to the subject in an amount sufficient to restrict a polarization of myelin basic protein specific T cells into Th2 cells.

54. A method of inducing protective immunity against multiple sclerosis in a subject, the method comprising directly or indirectly introducing anti-interferon gamma-inducible protein 10 antibodies to the subject in an amount sufficient to induce protective immunity against multiple sclerosis in the subject.

55. A method of preventing or treating multiple sclerosis in a subject, the method comprising directly or indirectly introducing anti-interferon gamma-inducible protein 10 antibodies to the subject in an amount sufficient to treat or prevent multiple sclerosis.